Caroline Davidge-Pitts

Caroline Davidge-Pitts

Auto-generated profile, based on publicly available information

Caroline Davidge-Pitts

Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic , Rochester, MN

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
HJHaleigh A. James
Haleigh A. James
ACAlice Y. Chang
Alice Y. Chang
RIReese L. Imhof
Reese L. Imhof
ASAradhana Sahoo
Aradhana Sahoo
MMMonique M. Montenegro
Monique M. Montenegro
CDCaroline J. Davidge-Pitts
Caroline J. Davidge-Pitts
Background: Current understanding about health care in the gender diverse population is limited by the lack of community-based, longitudinal data, especially in the USA. We sought to characterize a community-based cohort of transgender individuals including demographics, gender identities, social characteristics, psychiatric and medical conditions, and medical therapy for gender dysphoria/incongruence. Patients and methods: We performed a retrospective chart review of gender diverse residents of Olmsted County, Minnesota, who sought gender-specific healthcare from January 1, 1974, through December 31, 2015, using an infrastructure that links medical records of Olmsted County residents from multiple institutions. Results: The number of patients seeking gender-specific healthcare increased from 1 to 2 per 5-year interval during the 1970s–1990s to 41 from 2011 to 2015 (n = 82). Forty-nine (59.8%) were assigned male sex at birth (AMAB), 31 (37.8%) were assigned female (AFAB), and 2 (2.4%) were intersex. Gender identities evolved over time in 16.3% and 16.1% of patients AMAB and AFAB, respectively, and at most recent follow-up, 8.2% and 12.9% of patients AMAB and AFAB, respectively, were non-binary. Depression affected 78%, followed by anxiety (62.2%), personality disorder (22%), and post-traumatic stress disorder (14.6%). 58.5% experienced suicidal ideation, 22% attempted suicide, and 36.6% were victims of abuse. The most prevalent medical conditions and cardiovascular (CV) risk factors included obesity (42.7%), tobacco use (40.2%), fracture [34.1% (86.2% traumatic)], hypertension (25.6%), hyperlipidemia (25.6%), and hypertriglyceridemia (15.9%). 67.3% of patients AMAB used feminizing and 48.4% of patients AFAB used masculinizing hormone therapy. When compared to US CDC National Health Statistics, there was a significantly greater prevalence of depression and anxiety but no difference in the prevalence of obesity, hypertension, hypercholesterolemia, type 2 diabetes, or stroke. Conclusion: Transgender and gender diverse individuals represent a population who express various gender identities and are seeking gender-specific healthcare at increasing rates. Psychiatric illness is highly prevalent compared to the US population but there is no difference in the prevalence of CV risk factors including obesity, type 2 diabetes, hypertension, and dyslipidemia.

24 June 2022 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
CGChristopher S Graffeo
Christopher S Graffeo
KYKaran J. Yagnik
Karan J. Yagnik
LCLucas P. Carlstrom
Lucas P. Carlstrom
NLNikita Lakomkin
Nikita Lakomkin
IBIrina Bancos
Irina Bancos
JGJamie J Van Gompel
Jamie J Van Gompel

2 November 2023 in Blood
Verified
Journal Article
Closed access
PDF file
AAAldo A. Acosta-Medina
Aldo A. Acosta-Medina
PKPaul Geraeds Kemps
Paul Geraeds Kemps
TZTimo C. E. Zondag
Timo C. E. Zondag
Jithma AbeykoonJithma Abeykoon
Jithma Abeykoon
JFJelske Forma-Borst
Jelske Forma-Borst
AHAstrid G.S. van Halteren
Astrid G.S. van Halteren
In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers, which may be clonally related.

1 June 2019 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
OHOksana Hamidi
Oksana Hamidi
CDCaroline J. Davidge-Pitts
Caroline J. Davidge-Pitts

16 April 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
AMArvind Maheshwari
Arvind Maheshwari
TNTodd Nippoldt
Todd Nippoldt
CDCaroline Davidge-Pitts
Caroline Davidge-Pitts
Nonsuppressed levels of testosterone are seen in up to a quarter of transgender women on gender-affirming feminizing hormonal treatment. Multiple factors contribute to this situation, including patient, medication, laboratory, and organ-specific concerns. We propose a stepwise approach to determine the etiology of nonsuppressed levels of testosterone in transgender women. This may lead to an appropriate feminizing hormonal therapy regimen and diagnosis of manageable medical conditions.

17 April 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
JHJustine Herndon
Justine Herndon
NGNidhi Gupta
Nidhi Gupta
CDCaroline Davidge-Pitts
Caroline Davidge-Pitts
NINicole Imhof
Nicole Imhof
CGCesar Gonzalez
Cesar Gonzalez
ACAlice Y Chang
Alice Y Chang
Context Transgender and gender diverse (TGD) individuals have greater access to genital surgery (GS) with improved insurance coverage and access to trained surgeons and interdisciplinary gender-affirming providers. Objective To determine perioperative medical and behavioral health outcomes in transfeminine (TF) individuals undergoing GS, with use of a specific gender-affirming hormone therapy (GAHT) algorithm based on individualized risk factor assessment. Methods In this retrospective observational cohort study, we collected preoperative and postoperative data from 183 TF individuals at a single tertiary referral center from 2017 to 2022, grouping patients by those who continued estradiol (Group 1) vs those who had temporarily discontinued estradiol for 2 to 6 weeks preoperatively (Group 2). Data included clinical and biochemical assessment, GAHT regimens, validated behavioral health measures, and postoperative complications. Main outcomes included venous thromboembolism (VTE) incidence, non-VTE postoperative complication incidence, and change in behavioral health assessments. Results The majority of individuals continued estradiol perioperatively (Group 1; 138 [75.4%]). Individuals who temporarily held estradiol preoperatively (Group 2; 45 [24.6%]) were statistically older (P < .01), had higher incidence of cardiometabolic comorbidities (P < .01), and higher Caprini scores (P < .01). Group 1 was statistically more likely to use oral estradiol (P < .01). One episode (0.05%) of VTE occurred (Group 1). There was no significant difference in postoperative complications or behavioral health measures between groups. Conclusion An individualized algorithm for preoperative hormone management for TF GS resulted in perioperative continuation of GAHT for the majority of individuals without significantly increasing the risk for postoperative surgical complications, while maintaining stable behavioral health measures perioperatively.